Harrow Health, Inc.

HROW

NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

Nashville, TN, US382 employeesharrowinc.com

$35.34

-0.09(-0.25%)

Mkt Cap $1.3B

$22.20

$54.80

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product Sales Net (81.3%), IHEEZO (7%), VEVYE (5.5%).

8-K

Harrow, Inc. launched a private offering to sell $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 under the same indenture as its existing $250 million notes issued on September 12, 2025. Net proceeds are intended for general corporate purposes, including growth initiatives like new product launches, product development, and strategic opportunities.

$1.3B

Market Cap

$276M

Revenue

-$5M

Net Income

Employees382

Fundamentals

How The Business Makes Money

Revenue by Segment

Product Sales Net81.3%($1.8B)

IHEEZO7%($151M)

VEVYE5.5%($119M)

Other Products3.6%($78M)

Other Revenues2%($42M)

Other Revenue0.6%($14M)

Activity

What Changed Recently

Financial Results

Mar 1, 2026

. Results of Operations and Financial Condition. On March 2, 2026, Harrow, Inc. (the “Company”) issued a press release and a letter to stockholders announcing i

Financial Results

Feb 1, 2026

and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be

Other Event

Mar 23, 2026

. Other Events. On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release to announce the launch of its offer to sell $50.0 million aggregate princ

Other Event

Mar 23, 2026

. Other Events. On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $50.0 million aggregate princip

Regulation FD

Mar 9, 2026

(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “

Peer Companies

Company	Price	Change	Market Cap	P/E
DVAXDVAX	$15.50	+0.00%	$1.8B	—
TRVITrevi Therapeutics, Inc.	$11.93	+3.02%	$1.5B	-36.6
KMTSKESTRA MEDICAL TECHNOLOGI...	$19.82	-1.15%	$1.2B	-7.1
ALVOAlvotech	$3.65	+0.69%	$1.1B	14.4
COLLCollegium Pharmaceutical,...	$32.27	-2.93%	$1.0B	17.5
BLFSBioLife Solutions, Inc.	$19.47	+0.93%	$940M	-75.5
AMPHAmphastar Pharmaceuticals...	$20.44	+0.99%	$939M	9.0
EVOEvotec SE	$2.58	+1.57%	$917M	-4.7

Analyst View

Company Profile

CIK0001360214

ISINUS4158581094

CUSIP415858109

Phone615 733 4730

Address102 Woodmont Boulevard, Nashville, TN, 37205, US

SEC EDGAR